The Y2 receptor mediates increases in collateral-dependent blood flow in a model of peripheral arterial insufficiency

Peptides

Volumn 28, Issue 2, 2007, Pages 269-280

  Cruze, Charles A ^a   Su, Frank ^a   Limberg, Brian J ^a   Deutsch, Angela J ^a   Stoffolano, Peter J ^a   Dai, H Jian ^a   Buchanan, Danielle D ^a   Yang, H T ^b   Terjung, Ronald L ^b   Spruell, Russell D ^a   Mittelstadt, Scott W ^a   Rosenbaum, Jan S ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Angiogenesis; Arteriogenesis; Collateral blood flow; Intermittent claudication; NPY; Peripheral arterial disease (PAD); PYY; PYY3 36; Therapeutic angiogenesis; Vascular remodeling; Y2 receptor

Indexed keywords

CYCLIC AMP; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PEPTIDE YY; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG; VASCULOTROPIN 165; NEUROPEPTIDE Y RECEPTOR; PRIMER DNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTERY DISEASE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORNEA VASCULARIZATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; FEMALE; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; MALE; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL ISCHEMIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; ANIMAL; BIOLOGICAL MODEL; CIRCULATION; HUMAN; METABOLISM; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BASE SEQUENCE; BLOOD CIRCULATION; DNA PRIMERS; FEMALE; HUMANS; MODELS, BIOLOGICAL; PERIPHERAL VASCULAR DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33846560660     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.09.026     Document Type: Article

References (37)

1. Ariens E.J. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99 (1954) 32-49
2. Asahara T., Chen D.H., Takahashi T., Fujikawa K., Kearney M., Magner M., et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83 (1998) 233-240
3. Brumovsky P., Stanic D., Shuster S., et al. Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse. J Comp Neurol 489 (2005) 328-348
4. Cao R.H., Eriksson A., Kubo H., Alitalo K., Cao Y.H., and Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94 (2004) 664-670
5. Carmeliet P., and Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 436 (2005) 193-200
6. Chalasani S.H., Sabelko K.A., Sunshine M.J., et al. A chemokine, SDF-1, reduces the effectiveness of multiple axonal repellents and is required for normal axon path finding. J Neurosci 23 (2003) 1360-1371
7. Clarke W.P., and Bond R.A. The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19 (1998) 270-276
8. Collister J.P., and Hendel M.D. Role of the subfornical organ in the chronic hypotensive response to losartan in normal rats. Hypertension 41 (2003) 576-582
9. Dumont Y., Thakur M., Beck-Sickinger A., et al. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP. Neuropeptides 38 (2004) 163-174
10. Ekstrand A.J., Cao R., Bjorndahl M., et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 100 (2003) 6033-6038
11. Guedez L., Rivera A.M., Salloum R., Miller M.L., Diegmueller J.J., Bungay P.M., et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 162 (2003) 1431-1439
12. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 (2006) 547-553
13. Hansel D.E., Eipper B.A., and Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (2001) 940-944
14. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47 (2006) 1239-1312
15. Howell O.W., Doyle K., Goodman J.H., et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem 93 (2005) 560-570
16. Jacoby D., and Mohler E.R. Drug treatment of intermittent claudication. Drugs 64 (2004) 1657-1670
17. Keire D.A., Bowers C.W., Solomon T.E., and Reeve J. Structure and receptor binding of PYY analogs. Peptides 23 (2002) 305-321
18. Kenyon B.M., Voest E.E., Chen C.C., et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37 (1996) 1625-1632
19. Kluk M.J., and Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta (BBA): Mol Cell Biol Lipids 1582 (2002) 72-80
20. Lee E.W., Grant D.S., Movafagh S., and Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24 (2003) 99-106
21. Lee E.W., Michalkiewicz M., Kitlinska J., et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 111 (2003) 1853-1862
22. Lee E., Grant D.S., Movafagh S., and Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24 (2003) 99-106
23. Li L., Jonsson-Rylander A.C., Abe K., and Zukowska Z. Chronic stress induces rapid occlusion of angioplasty-injured rat carotid artery by activating neuropeptide Y and its Y1 receptors. Arterioscler Thromb Vasc Biol 25 (2005) 2075-2080
24. Merten N., and Beck-Sickinger A.G. Molecular ligand-receptor interaction of the NPY/PP peptide family. EXS (2006) 35-62
25. Morris M.J. Neuropeptide Y and cardiovascular function. In: Michel M.C. (Ed). Neuropeptide Y and related peptides (2004), Springer-Verlag, Berlin 327-359
26. Parker M.S., Crowley W.R., and Parker S.L. Differences in cation sensitivity of ligand binding to Y1 and Y2 subtype of neuropeptide Y receptor of rat brain. Eur J Pharmacol 318 (1996) 193-200
27. Poonawala T., Levay-Young B.K., Hebbel R.P., and Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen 13 (2005) 165-174
28. Salcedo R., and Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10 (2003) 359-370
29. Simons M. Angiogenesis: where do we stand now?. Circulation 111 (2005) 1556-1566
30. Simons M., and Ware J.A. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2 (2003) 863-871
31. Srivastava S., Terjung R.L., and Yang H.T. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart Circ Phys 285 (2003) H1190-H1197
32. Stephenson R.P. A modification of receptor theory. Br J Pharmacol Chemother 11 (1956) 379-393
33. Wagner J.G. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20 (1968) 173-201
34. Walker M.W., and Miller R.J. 125I-neuropeptide Y and 125I-peptide YY bind to multiple receptor sites in rat brain. Mol Pharmacol 34 (1988) 779-792
35. Yang H.T., Feng Y., Allen L.A., Protter A., and Terjung R.L. Efficacy and specificity of bFGF increased collateral flow in experimental peripheral arterial insufficiency. Am J Physiol Heart Circ Phys 278 (2000) H1966-H1973
36. Zukowska Z., Grant D.S., and Lee E.W. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trend Cardiovasc Med 13 (2003) 86-92
37. Zukowska Grojec Z., Karwatowska Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., et al. Neuropeptide Y-a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83 (1998) 187-195